Intarcia may finally get its post-CRL review, although FDA points to Covid and another hearing as taking priority

Zachary Brennan

Senior Editor

Intarcia Therapeutics, once valued at more than $5 billion and attracting investors like the Bill & Melinda Gates Foundation, is now tussling with the FDA’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Intarcia may finally get its post-CRL review, although FDA points to Covid and another hearing as taking priority

Zachary Brennan

Senior Editor

Sign up to read this article for free.

After stock slides, Amgen addresses bone density talk on obesity drug

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Intar­cia may fi­nal­ly get its post-CRL re­view, al­though FDA points to Covid and an­oth­er hear­ing as tak­ing pri­or­i­ty

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Intarcia may finally get its post-CRL review, although FDA points to Covid and another hearing as taking priority

After stock slides, Amgen addresses bone density talk on obesity drug

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?